These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28586221)

  • 1. The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors.
    Strong KL; Epplin MP; Bacsa J; Butch CJ; Burger PB; Menaldino DS; Traynelis SF; Liotta DC
    J Med Chem; 2017 Jul; 60(13):5556-5585. PubMed ID: 28586221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of
    Strong KL; Epplin MP; Ogden KK; Burger PB; Kaiser TM; Wilding TJ; Kusumoto H; Camp CR; Shaulsky G; Bhattacharya S; Perszyk RE; Menaldino DS; McDaniel MJ; Zhang J; Le P; Banke TG; Hansen KB; Huettner JE; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2021 Jan; 12(1):79-98. PubMed ID: 33326224
    [No Abstract]   [Full Text] [Related]  

  • 3. A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.
    Swanger SA; Vance KM; Acker TM; Zimmerman SS; DiRaddo JO; Myers SJ; Bundgaard C; Mosley CA; Summer SL; Menaldino DS; Jensen HS; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2018 Feb; 9(2):306-319. PubMed ID: 29043770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.
    Santangelo Freel RM; Ogden KK; Strong KL; Khatri A; Chepiga KM; Jensen HS; Traynelis SF; Liotta DC
    J Med Chem; 2013 Jul; 56(13):5351-81. PubMed ID: 23627311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.
    Acker TM; Khatri A; Vance KM; Slabber C; Bacsa J; Snyder JP; Traynelis SF; Liotta DC
    J Med Chem; 2013 Aug; 56(16):6434-56. PubMed ID: 23909910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.
    Khatri A; Burger PB; Swanger SA; Hansen KB; Zimmerman S; Karakas E; Liotta DC; Furukawa H; Snyder JP; Traynelis SF
    Mol Pharmacol; 2014 Nov; 86(5):548-60. PubMed ID: 25205677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.
    Perszyk RE; DiRaddo JO; Strong KL; Low CM; Ogden KK; Khatri A; Vargish GA; Pelkey KA; Tricoire L; Liotta DC; Smith Y; McBain CJ; Traynelis SF
    Mol Pharmacol; 2016 Dec; 90(6):689-702. PubMed ID: 27625038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor.
    Kaiser TM; Kell SA; Kusumoto H; Shaulsky G; Bhattacharya S; Epplin MP; Strong KL; Miller EJ; Cox BD; Menaldino DS; Liotta DC; Traynelis SF; Burger PB
    Mol Pharmacol; 2018 Feb; 93(2):141-156. PubMed ID: 29242355
    [No Abstract]   [Full Text] [Related]  

  • 9. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
    Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
    Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit.
    Buemi MR; De Luca L; Ferro S; Russo E; De Sarro G; Gitto R
    Bioorg Med Chem; 2016 Apr; 24(7):1513-9. PubMed ID: 26912202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Dihydropyrrolo[1,2-
    Epplin MP; Mohan A; Harris LD; Zhu Z; Strong KL; Bacsa J; Le P; Menaldino DS; Traynelis SF; Liotta DC
    J Med Chem; 2020 Jul; 63(14):7569-7600. PubMed ID: 32538088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the
    D'Erasmo MP; Akins NS; Ma P; Jing Y; Swanger SA; Sharma SK; Bartsch PW; Menaldino DS; Arcoria PJ; Bui TT; Pons-Bennaceur A; Le P; Allen JP; Ullman EZ; Nocilla KA; Zhang J; Perszyk RE; Kim S; Acker TM; Taz A; Burton SL; Coe K; Fritzemeier RG; Burnashev N; Yuan H; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2023 Sep; 14(17):3059-3076. PubMed ID: 37566734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel family of negative and positive allosteric modulators of NMDA receptors.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Skifter DA; Jane DE; Monaghan DT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):614-21. PubMed ID: 20858708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In the Telencephalon, GluN2C NMDA Receptor Subunit mRNA is Predominately Expressed in Glial Cells and GluN2D mRNA in Interneurons.
    Alsaad HA; DeKorver NW; Mao Z; Dravid SM; Arikkath J; Monaghan DT
    Neurochem Res; 2019 Jan; 44(1):61-77. PubMed ID: 29651654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines.
    Benner A; Bonifazi A; Shirataki C; Temme L; Schepmann D; Quaglia W; Shoji O; Watanabe Y; Daniliuc C; Wünsch B
    ChemMedChem; 2014 Apr; 9(4):741-51. PubMed ID: 24677663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.
    Nouhi M; Zhang X; Yao N; Chergui K
    CNS Neurosci Ther; 2018 Feb; 24(2):144-153. PubMed ID: 29230960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine depletion of the striatum causes a cell-type specific reorganization of GluN2B- and GluN2D-containing NMDA receptors.
    Zhang X; Chergui K
    Neuropharmacology; 2015 May; 92():108-15. PubMed ID: 25619731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of AICP as a GluN2C-Selective
    Jessen M; Frederiksen K; Yi F; Clausen RP; Hansen KB; Bräuner-Osborne H; Kilburn P; Damholt A
    Mol Pharmacol; 2017 Aug; 92(2):151-161. PubMed ID: 28588066
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.
    Monaghan DT; Irvine MW; Costa BM; Fang G; Jane DE
    Neurochem Int; 2012 Sep; 61(4):581-92. PubMed ID: 22269804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792.
    Sapkota K; Burnell ES; Irvine MW; Fang G; Gawande DY; Dravid SM; Jane DE; Monaghan DT
    Neuropharmacology; 2021 Dec; 201():108818. PubMed ID: 34610288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.